Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab′)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels*

@article{Panacek2004EfficacyAS,
  title={Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab′)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels*},
  author={Edward A. Panacek and John C. Marshall and Timothy E. Albertson and David H. Johnson and Steven B. Johnson and Rodger D. MacArthur and Mark A. Miller and William T. Barchuk and Steven A. Fischkoff and Martin Kaul and Leah Teoh and Lori Van Meter and Lothar Dr Daum and Stanley Lemeshow and Greg A Hicklin and Christopher James Doig},
  journal={Critical Care Medicine},
  year={2004},
  volume={32},
  pages={2173-2182}
}
Objective:To evaluate whether administration of afelimomab, an anti-tumor necrosis factor F(ab′)2 monoclonal antibody fragment, would reduce 28-day all-cause mortality in patients with severe sepsis and elevated serum levels of IL-6. Design:Prospective, randomized, double-blind, placebo-controlled, multiple-center, phase III clinical trial. Setting:One hundred fifty-seven intensive care units in the United States and Canada. Patients:Subjects were 2,634 patients with severe sepsis secondary to… 
Safety and efficacy of affinity-purified, anti–tumor necrosis factor-&agr;, ovine fab for injection (CytoFab) in severe sepsis*
TLDR
CytoFab is well tolerated in patients with severe sepsis, effectively reducing serum and BAL TNF-&agr; and serum IL-6 concentrations and increasing the number of ventilator-free and ICU-free days at day 28.
Afelimomab led to a modest mortality benefit in patients with severe sepsis and elevated interleukin-6 levels
TLDR
The primary outcome was 28-day all-cause mortality and secondary outcomes included improvement in organ dysfunction, reduction in TNF and IL-6 levels, and safety.
Enhanced survival from CLP-induced sepsis following late administration of low doses of anti-IFNγ F(ab′)2 antibody fragments
TLDR
Delicate modulation of IFNγ at the correct timing, even when the septic process has begun, is an exciting alternative to explore in the treatment of sepsis.
Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial.
TLDR
Biomarker-guided GM-CSF therapy in sepsis is safe and effective for restoring monocytic immunocompetence and may shorten the time of mechanical ventilation and hospital/intensive care unit stay.
Personalized medicine with IgGAM compared with standard of care for treatment of peritonitis after infectious source control (the PEPPER trial): study protocol for a randomized controlled trial
TLDR
This study aims to combine an assessment of the efficacy of treatment with a preparation of human immunoglobulins G, A, and M with individual status of various biomarkers and test the hypothesis that patients receiving IgGAM who have higher inflammation status (IL-6) and poorer immune status have a better outcome than patients who do not receive IgG AM.
Positive effect of septimeb™ on mortality rate in severe sepsis: a novel non antibiotic strategy
TLDR
Septimeb reduces mortality rates among patients with severe sepsis and it could be added as a safe adjutant to standard treatment of sepsi, according to this multicenter, randomized, single-blind trial.
Prognostic serum tumor necrosis factor-α in paediatric patients with sepsis
TLDR
TNF-α was significantly raised in culture-positive cases in general and in gram-negative infections in particular and can be used as a surrogate marker of sepsis and aggressive treatment initiated in patients with elevated levels of TNF alpha.
The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial
TLDR
The use of Tα1 therapy in combination with conventional medical therapies may be effective in improving clinical outcomes in a targeted population of severe sepsis.
Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock*
TLDR
This study found no predictable correlation between serum levels of HMGB1 and severity of infection, and levels remained high in the majority of patients up to 1 wk after admittance, indicating that the cytokine indeed is a downstream and late mediator of inflammation.
Emerging drugs for the treatment of sepsis
TLDR
Meta-analysis of conducted trials disclosed the decrease of mortality in septic shock after administration of immunoglobulin preparations enriched with IgM, indicating the need for agents that modulate the immune function of the host.
...
...

References

SHOWING 1-10 OF 62 REFERENCES
Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study.
OBJECTIVE To investigate the safety, biological effects, and efficacy of the anti-tumor necrosis factor (TNF) antibody fragment, MAK 195F, in a phase II trial in patient with severe sepsis. DESIGN
Influence of an anti‐tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis
TLDR
The murine monoclonal anti-TNF antibody was well tolerated despite the development of anti-murine antibodies in 98% of patients and no survival benefit was found for the total study population.
Efficacy and Safety of Monoclonal Antibody to Human Tumor Necrosis Factor α in Patients With Sepsis Syndrome: A Randomized, Controlled, Double-blind, Multicenter Clinical Trial
TLDR
There was no decrease in mortality between placebo and TNF-α MAb in all infused patients, and in septic shock patients who received T NF- α MAb, a significant reduction in mortality was present 3 days after infusion; however, although a trend toward reduced mortality continued at 28 days following treatment with TTFMAb, the difference in mortality among shock patients treated with placebo or TFB was not significant.
Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.
TLDR
There was no decrease in mortality between placebo and TNF-alpha MAb in all infused patients, and in septic shock patients who received TNF, a significant reduction in mortality was present 3 days after infusion.
p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group.
TLDR
A prospectively planned logistic regression analysis to assess treatment effect on 28-day all-cause mortality by means of predicted mortality and serum interleukin 6 levels as continuous covariates demonstrated a significant improvement in outcome for the patients with severe sepsis treated with p55-IgG.
INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group.
TLDR
IntERSEPT provides additional clinical data implicating TNF-alpha as an integral mediator of septic shock and suggested a possible role for anti-TNF antibody as adjunctive therapy, but this possibility requires confirmation by another clinical trial.
TREATMENT OF SEPTIC SHOCK WITH THE TUMOR NECROSIS FACTOR RECEPTOR : Fc FUSION PROTEIN C
TLDR
In patients with septic shock, treatment with the TNFR:Fc fusion protein does not reduce mortality, and higher doses appear to be associated with increased mortality.
Plasma tumor necrosis factor levels in patients with presumed sepsis. Results in those treated with antilipid A antibody vs placebo.
TLDR
Tumor necrosis factor levels did not predict adult respiratory distress syndrome, shock, disseminated intravascular coagulation, renal failure, or mortality, and 2 patients with bacteremia repeatedly had detectable TNF levels and a clinical picture consistent with gram-negative sepsis.
Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group.
TLDR
The safety and efficacy of murine monoclonal antibody to human tumour necrosis factor alpha (TNF alpha MAb) in the treatment of septic shock is assessed and therapy not solely dependent on TNF alpha blockade may be required to improve survival.
p55 Tumor Necrosis Factor Receptor Fusion Protein in the Treatment of Patients With Severe Sepsis and Septic Shock: A Randomized Controlled Multicenter Trial
TLDR
A prospectively planned logistic regression analysis to assess treatment effect on 28-day all-cause mortality by means of predicted mortality and serum interleukin 6 levels as continuous covariates demonstrated a significant improvement in outcome for the patients with severe sepsis treated with p55-lgG.
...
...